Strategic Support

Seventh Wave actively integrates preclinical drug disposition (ADME and PK/PD), toxicology, and pathology data to streamline decision making and increase the probability of technical success for a clinical candidate.

This integration provides early characterization and optimization of the biochemical, biopharmaceutical, and toxicologic properties of clinical candidates resulting in more accurate predictions of dose-effect relationships in humans. And, our commitment to scientific continuity provides significant competitive advantages for clients during the approval and licensing part of the process.